The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Urgency, frequency and incomplete emptying are the key symptoms of lower urinary tract dysfunction, including bladder pain syndrome/interstitial cystitis, and overactive bladder syndrome. Lower urinary tract dysfunction is associated with cellular stress, leading to changes in gene expression and consequent organ remodeling. MicroRNAs are small regulatory molecules, affecting protein synthesis. They are quickly winning recognition as potential therapeutic agents. The investigators will perform a comparative study of mRNAs changed in lower urinary tract dysfunction and address the role of differentially expressed miRNAs in regulation of the genes, important for bladder function. The experimental approach, combining the analysis of human biopsy material with the in vitro cell-based models, will allow the investigators to elucidate the effects of miRNAs on the expression of receptors, contractile proteins and tight junction proteins. Once the disease-induced miRNAs have been characterised and their target genes validated, it will be possible to influence their expression levels thus counter-acting their effects.
The investigators' work addresses fundamental mechanisms of signal transduction in urothelium and smooth muscle during cellular stress caused by inflammation or bladder outlet obstruction, and its regulation in the diseased state. The investigators' findings will further the knowledge of the molecular mechanisms of lower urinary tract dysfunction and have implications for diagnosis and treatment. Additionally, they have relevance for other clinical conditions, where miRNAs are implicated.
| Condition |
|---|
|
Prostatic Hyperplasia Urinary Bladder Neck Obstruction Cystitis, Interstitial |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | Investigating the Role of microRNAs in the Regulation of Gene Expression and Organ Remodeling During Lower Urinary Tract Dysfunction, Including Bladder Pain Syndrome/Interstitial Cystitis (BPS), and Overactive Bladder Syndrome (OAB) |
- Molecular traits of bladder dysfunction [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- MiRNA expression profiling of individual groups [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- Protein expression profiling of individual groups [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- Functional differences between groups [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Frozen cold-cut bladder biopsies preserved in RNAlater buffer or in SDS-PAGE sample buffer; PFA-fixed tissue, primary cultures of urothelium and smooth muscle
| Estimated Enrollment: | 80 |
| Study Start Date: | October 2010 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
controls (normal bladder function)
|
|
2
acontractile bladder
|
|
3
overactive bladder
|
|
4
bladder pain syndrome
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients Department of Urology, Inselspital Bern, Switzerland
Inclusion Criteria:
- prostate hyperplasia
- bladder acontractility
- bladder pain
- age over 18 years old
- willingness to participate (informed concent)
Exclusion Criteria
- Age ≤ 18 years old
- Pregnancy
- History of or current genito-urinary tuberculosis
- History of pelvic surgery in the last 6 months
- History of bladder malignancy, high grade dysplasia or carcinoma in situ
- sexually transmitted diseases (STD's)
- Bacteriuria
Contacts and Locations| Contact: Fiona C Burkhard, Prof Dr med | +41 31 632 36 41 | Fiona.Burkhard@insel.ch |
| Contact: Katia Monastyrskaya, PhD | + 41 31 632 87 19 | monastyk@dkf.unibe.ch |
| Switzerland | |
| Department of Urology, Bern University hospital | Recruiting |
| Bern, Switzerland, 3010 | |
| Principal Investigator: Katia Monastyrskaya, PhD | |
| Principal Investigator: Fiona C Burkhard, Prof Dr | |
| Principal Investigator: | Katia Monastyrskaya, PhD | Department of Urology, Bern University hospital |
More Information
Publications:
| Responsible Party: | PD Dr Katia Monastyrskaya, Urology Research Laboratory, Department Clinical Research, University of Bern |
| ClinicalTrials.gov Identifier: | NCT01482676 History of Changes |
| Other Study ID Numbers: | 146/05b |
| Study First Received: | November 17, 2011 |
| Last Updated: | January 11, 2013 |
| Health Authority: | Switzerland: Ethikkommission |
Additional relevant MeSH terms:
|
Prostatic Hyperplasia Urinary Bladder Neck Obstruction Cystitis Hyperplasia Cystitis, Interstitial Prostatic Diseases |
Genital Diseases, Male Urethral Obstruction Urethral Diseases Urologic Diseases Urinary Bladder Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013